Sanara MedTech Reports Q1 Profitability, 19% Revenue Growth, Reaffirms Full-Year Guidance
SMTI sits 20% above its 52-week low of $16.047.
Summary
Sanara MedTech reported a return to net profitability and strong 19% revenue growth in Q1 2026, validating its strategic focus on the surgical market and reaffirming full-year guidance.
Key Events · Earnings and Guidance · SMTI
-
Return to Profitability
Sanara MedTech reported net income of $0.4 million ($0.04 per diluted share) from continuing operations in Q1 2026, a significant improvement from a net loss of $0.6 million ($0.07 per diluted share) in Q1 2025.
-
Strong Revenue Growth
Net revenue increased 19% year-over-year to $27.8 million, driven by increased sales of soft tissue repair products.
-
Improved Operating Performance
Gross profit margin expanded to 93%, and Adjusted EBITDA increased 58% to $4.3 million.
-
Guidance Reaffirmed
The company reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth, and provided Q2 2026 revenue guidance of $28.5 million to $29.5 million.
Analysis · SMTI · Industrial Applications And Services
This filing is highly important because it demonstrates the successful execution of Sanara MedTech's strategic realignment. The company achieved GAAP net profitability from continuing operations in Q1 2026, a significant turnaround from a loss in the prior year. This, coupled with strong 19% revenue growth and improved operating metrics, validates the company's focus on the surgical market. Reaffirming full-year guidance after such a strong quarter provides confidence in the company's future performance and financial stability.
At the time of this filing, SMTI was trading at $19.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $165.1M. The 52-week trading range was $16.05 to $35.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.